ImmunityBio Stock Drops After FDA Misleading Ad Warning

Key Summary of FDA Action

ImmunityBio's stock experienced a significant decline, falling as much as 30%, after the U.S. Food and Drug Administration issued a warning letter. The letter cited the company for false and misleading promotion of its bladder cancer drug, Anktiva.

Situation Overview

The FDA's warning, dated March 13, identified violations in promotional materials, including a television advertisement and a podcast. These materials allegedly made unsubstantiated claims that Anktiva could treat all cancers, a scope far beyond its approved indication for a specific type of bladder cancer when used with BCG therapy.

Impact on the Market

The regulatory action immediately impacted investor confidence, leading to a sharp sell-off of ImmunityBio shares upon market open. The FDA also noted the company's failure to properly disclose risk information and submit promotional materials as required, adding to market concerns about its compliance and marketing practices.

Conclusion

ImmunityBio has 15 working days to outline a corrective action plan to the FDA. Investors will be closely monitoring the company's response and any subsequent regulatory measures, which will be critical factors for the stock's future performance.

**FAQ**

**Q:** Why did ImmunityBio's stock price fall sharply?
**A:** The stock price fell after the company received a warning letter from the FDA regarding false and misleading advertisements for its drug, Anktiva.

**Q:** What were the misleading claims about Anktiva?
**A:** Promotional materials suggested Anktiva could treat and prevent a wide range of cancers, while its approval is limited to a specific type of bladder cancer.

Source: Investing.com